GCA is systemic immune-mediated vasculitis and is the most common type of arteritis. This retrospective study proved that GCA is a disease of older age and that it mainly occurs above the age of 50. After the age of 50, the incidence progressively increases and most of the respondents, 70,21% of them, were hospitalized over the age of 70. It occurs two to three times more often in women than in men. GCA symptoms can occur gradually or suddenly, and are generally not recognized on time. On average, most respondents, 25,58% of them, were hospitalized only four weeks after the first onset of symptoms. The most common symptoms are headache, which is present in 88,89% of respondents, followed by fever, fatigue and weight loss. Before diagnosing GCA and initiating therapy, all subjects in this study had elevated inflammatory parameters (SE and CRP). The diagnosis is made on the basis of the clinical picture and laboratory findings, and is confirmed by a positive pathohistological finding of the TA biopsy. Biopsy is also the gold standard in the diagnosis of GCA and is positive in 81,25% of subjects, although a negative finding does not exclude the diagnosis. Therapy should in principle be applied immediately, even if the biopsy needs to be postponed. The basis of GCA treatment is high doses of systemic GC. Immunosuppressive drugs such as AZA and MTX can be added in therapy. Their application leads to a reduction in the cumulative dose of GK and a smaller number of relapses of the disease itself. Recently, the use of the immunosuppressive drug TCZ, which is also a new and promising therapy in the treatment of GCA, is becoming more frequent.